Cristina E Tognon

Cristina E Tognon

UNVERIFIED PROFILE

Are you Cristina E Tognon?   Register this Author

Register author
Cristina E Tognon

Cristina E Tognon

Publications by authors named "Cristina E Tognon"

Are you Cristina E Tognon?   Register this Author

27Publications

752Reads

42Profile Views

Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Leukemia 2019 Sep 24. Epub 2019 Sep 24.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0576-8DOI Listing
September 2019

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.

PLoS One 2019 25;14(3):e0205623. Epub 2019 Mar 25.

Department of Molecular and Medical Genetics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205623PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433232PMC
March 2019

Functional genomic landscape of acute myeloid leukaemia.

Nature 2018 10 17;562(7728):526-531. Epub 2018 Oct 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0623-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280667PMC
October 2018

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Leukemia 2018 09 6;32(9):2025-2028. Epub 2018 Aug 6.

Department of Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0225-7
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0225-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168939PMC
September 2018

Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Oncogene 2018 04 2;37(17):2270-2284. Epub 2018 Feb 2.

Precision Medicine Research Center, Advanced Institutes of Convergence Technology, Seoul National University, Suwon, Gyeonggi-do, 16229, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-017-0102-2DOI Listing
April 2018

Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.

J Pediatr Hematol Oncol 2017 10;39(7):e359-e366

*Knight Cancer Institute, Oregon Health and Science University ‡Howard Hughes Medical Institute, Portland, OR †Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613078PMC
October 2017

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.

Cureus 2015 Dec 17;7(12):e414. Epub 2015 Dec 17.

Knight Cancer Institute, Oregon Health & Science University ; Howard Hughes Medical Institute Investigator Program, Howard Hughes Medical Institute ; Division of Hematology & Medical Oncology, Oregon Health & Science University ; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725740PMC
December 2015

Therapeutically Targetable ALK Mutations in Leukemia.

Cancer Res 2015 Jun;75(11):2146-50

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/75/11/2146.full.pd
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-1576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453002PMC
June 2015

Detecting and targetting oncogenic fusion proteins in the genomic era.

Biol Cell 2015 May 7;107(5):111-29. Epub 2015 Apr 7.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, U.S.A; Department of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/boc.201400096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837291PMC
May 2015

Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.

Cancer Cell 2015 May;27(5):682-97

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Molecular Oncology, British Columbia Cancer Research Center, Vancouver, BC V5Z 1L3, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.04.003DOI Listing
May 2015

IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.

Sci Signal 2012 Dec 18;5(255):ra92. Epub 2012 Dec 18.

Biological Sciences Platform, Sunnybrook Research Institute and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.2003184DOI Listing
December 2012

On translational regulation and EMT.

Semin Cancer Biol 2012 Oct 23;22(5-6):437-45. Epub 2012 Apr 23.

Institute of Protein Research, Pushchino, Moscow Region 142290, Russian Federation.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2012.04.007DOI Listing
October 2012

Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.

Expert Opin Ther Targets 2012 Jan 12;16(1):33-48. Epub 2012 Jan 12.

British Columbia Cancer Research Centre , Department of Molecular Oncology, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2011.638626DOI Listing
January 2012

ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.

Cancer Res 2011 Feb 9;71(3):1060-70. Epub 2010 Dec 9.

Department of Molecular Oncology, BC Cancer Research Center, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-3096DOI Listing
February 2011

Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Mol Cell Biol 2004 Jun;24(11):4636-50

Department of Pathology, BC Research Institute for Children's and Women's Health, 950 West 28th St., Vancouver, British Columbia V5Z 4H4, Canada.

View Article

Download full-text PDF

Source
http://mcb.asm.org/cgi/doi/10.1128/MCB.24.11.4636-4650.2004
Publisher Site
http://dx.doi.org/10.1128/MCB.24.11.4636-4650.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC416412PMC
June 2004

A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.

J Biol Chem 2004 Feb 9;279(8):6225-34. Epub 2003 Dec 9.

Department of Pathology, British Columbia Research Institute for Children's and Women's Health and the University of British Columbia, Vancouver, British Columbia V5Z4H4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M307388200DOI Listing
February 2004

ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.

Oncogene 2002 Aug;21(37):5684-95

Department of Pathology, BC Research Institute for Children's and Women's Health, and the University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1205669DOI Listing
August 2002